PROFUSA INC (PFSA)
NASDAQHealth CareMedical - DevicesSnapshot 2026-09-04
$2.72+3.82%
Close 2026-09-04 · 1-day change
NASDAQHealth CareMedical - DevicesSnapshot 2026-09-04
QuarterlyIQ Insights · PFSA
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -60.8% |
| Our one-year growth estimate | diamond | Not available |
Growth built into the price is above our model estimate.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
A comparable growth gap is not available.
The one-year revenue growth assumption on Valuation.
Model as of — · Company calendar date is not available
PFSA — legal / regulatory event — Notice of Delisting or Failure to
Dated 2026-08-31
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing On August 26, 2026, Profusa, Inc. (the “Company”) received a letter (the “Determination Letter”) from the Listing Qualifications Department of The Nasdaq Stock Market (“Nasdaq”) notifying the Company that following the effectiveness of its recent 1-for-4 reverse stock split, the Company had fewer than the 500,000 publicly held shares required under Nasdaq Listing Rule 5550(a)(4) (the “Publicly…
Why it matters: Refinancing is a condition for the G3 acquisition. Delays could hinder the deal.
Supportive ifProfusa says it has refinanced or paid off G3's specific debts.
Worry ifNo progress reported on refinancing efforts by the next earnings call.
Why it matters: The company needs to meet Nasdaq rules to stay listed. Failure could lead to delisting.
Worry ifThe company meets Nasdaq Listing Rule 5450(b)(1)(C) again.
Less concerning ifThe company does not meet Nasdaq compliance rules again.
Why it matters: This financing is crucial for Profusa to exercise its option to acquire G3. It indicates financial health and growth potential.
Supportive ifProfusa gets financing commitments of at least $30 million.
Worry ifProfusa does not get the needed financing commitments.
Why it matters: Completing this deal could help Profusa grow. It may also boost its market position.
Supportive ifA press release will confirm that the Bio Insights PanOmics asset deal is done.
Worry ifNo announcement of completion by the end of Q3 2026.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$616 on $10,000 · ±6.2% | How much price usually moves either way. |
| Bad day | $2,642 loss on $10,000 · 26.4% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $9,992 loss on $10,000 · 99.9% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: Following Nasdaq rules is key for Profusa's stock listing. Good news can help investors.
Supportive ifProfusa gets a note from Nasdaq that it meets listing rules after the stock split.
Worry ifNasdaq warns or plans to delist Profusa.
Why it matters: The audits are key to closing the acquisition. Delays could impact the deal.
Supportive ifG3 auditors say the audits for 2024 and 2025 will finish by mid-September.
Worry ifAudits are late past mid-September. This puts the acquisition timeline at risk.
Why it matters: Approval is needed to change Preferred Stock to common stock. This affects capital.
Supportive ifStockholders agree to change Preferred Stock into common stock.
Worry ifStockholders do not agree to change Preferred Stock.
Why it matters: Using this option could help Profusa make more money and grow its market.
Supportive ifProfusa uses the option and announces it has acquired G3 Vision Labs.
Worry ifProfusa fails to meet the conditions to exercise the option by the deadline.